Antiviral Activity of Technologically Processed Antibodies to CD4 Receptor against Influenza Infection

Bull Exp Biol Med. 2022 Dec;174(2):250-253. doi: 10.1007/s10517-023-05683-8. Epub 2023 Jan 5.

Abstract

The antiviral activity of technologically processed antibodies to CD4 receptor was evaluated a model of sublethal A/California/04/2009 (H1N1)pdm09-induced influenza infection in female BALB/c mice. The technologically processed antibodies increased animal survival rate by 50% in comparison with the placebo group (p<0.05), which correlated with significant inhibition of virus replication in the lungs (p<0.05). The reference drug Tamiflu increased mouse survival rate (by 47%), decreased the virus titer in the lungs, and prevented body weight loss (p<0.05 in comparison with the placebo group by all parameters). The intrinsic protective activity of technologically processed antibodies to CD4 receptor was demonstrated, which manifested in a decrease in viral load in the lower respiratory tract and an increase in the survival rate.

Keywords: CD4 receptor; Ergoferon; Raphamin; influenza А infection; technologically processed antibodies.

MeSH terms

  • Animals
  • Antibodies / therapeutic use
  • Antibodies, Viral
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • CD4 Antigens
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza, Human*
  • Lung
  • Mice
  • Mice, Inbred BALB C
  • Orthomyxoviridae Infections*

Substances

  • Antiviral Agents
  • CD4 Antigens
  • Antibodies
  • Antibodies, Viral